ConductScience.org, home
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
API referenceFor AI assistants

Trial · NCT03816891

Results by group1,842

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 1,842

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2a - Vixarelimab 360 mg SC QW-50.6Standard Error 6.99percentage change
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2a - Placebo SC QW-29.4Standard Error 6.80percentage change
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2b - Vixarelimab 540 mg SC Q4W (DBL)-56.2Standard Error 4.84percentage change
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2b - Vixarelimab 360 mg SC, Q4W (DBL)-51.0Standard Error 4.83percentage change
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2b - Vixarelimab 120 mg SC, Q4W (DBL)-33.0Standard Error 4.86percentage change
Phase 2a & 2b: Percent Change From Baseline in Weekly Average Worst Itch-Numeric Rating Scale (WI-NRS) ScorePhase 2b - Placebo SC, Q4W (DBL), Then Vixarelimab (OLE)-14.5Standard Error 4.76percentage change
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 8Phase 2a - Vixarelimab 360 mg SC QW52.295% Confidence Interval 30.6 to 73.2percentage of participants
Phase 2a: Percentage of Participants Achieving at Least a 4-point Reduction From Baseline in Weekly Average WI-NRS at Week 8Phase 2a - Placebo SC QW30.895% Confidence Interval 14.3 to 51.8percentage of participants
Phase 2a: Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Week 8Phase 2a - Vixarelimab 360 mg SC QW-54.4Standard Error 7.03percentage change
Phase 2a: Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Week 8Phase 2a - Placebo SC QW-32.6Standard Error 6.96percentage change
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Vixarelimab 360 mg SC QWWeek 1-1.6Standard Error 0.36score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Placebo SC QWWeek 1-0.8Standard Error 0.29score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Vixarelimab 360 mg SC QWWeek 2-2.4Standard Error 0.47score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Placebo SC QWWeek 2-1.3Standard Error 0.30score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Vixarelimab 360 mg SC QWWeek 3-2.9Standard Error 0.52score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Placebo SC QWWeek 3-1.9Standard Error 0.37score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Vixarelimab 360 mg SC QWWeek 4-3.7Standard Error 0.62score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Placebo SC QWWeek 4-2.3Standard Error 0.42score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Vixarelimab 360 mg SC QWWeek 5-4.2Standard Error 0.66score on a scale
Phase 2a: Change From Baseline in Weekly Average of WI-NRS Over TimePhase 2a - Placebo SC QWWeek 5-2.6Standard Error 0.39score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03816891/results

API referenceFor AI assistants